Information Provided By:
Fly News Breaks for November 13, 2019
Nov 13, 2019 | 06:28 EDT
BofA/Merrill analyst Jason Gerberry initiated coverage of Exelixis with a Buy rating and $22 price target. The analyst expects the shares to rebound following a difficult few quarters ahead of ahead of the Phase 3 catalysts for lead drug Cabometyx. He sees a better entry point following the stock's recent selloff.
News For EXEL From the Last 2 Days
There are no results for your query EXEL